Navigation Links
Patient Disparities Seen in Lung Cancer Drug Trials

WEDNESDAY, July 6 (HealthDay News) -- Women, older people and minorities are under-represented in lung cancer drug trials in the United States, according to a new study.

Researchers say that this could have a significant impact on the efficacy and safety of new treatments among these groups, particularly the elderly.

"Our results suggest that the trial population used for approval of drugs do not represent well the U.S. population who may receive the marketed agent," the study's principal investigator, Dr. Shakun Malik, a medical officer at the U.S. Food and Drug Administration in Silver Spring, Md., said in a news release.

"This fact is concerning particularly for older patients who may experience greater toxicity when given the same dose and combination of drugs based on testing in a younger population," Malik explained in the release from the International Association for the Study of Lung Cancer.

In conducting the study, which was slated for presentation Wednesday at the 14th World Conference on Lung Cancer in Amsterdam, researchers reviewed 10 years of trial data for the treatment of non-small cell lung cancer submitted to the U.S. Food and Drug Administration.

The study revealed that although 42 percent of patients diagnosed with lung cancer in the United States between 1975 and 2008 were women, only 32 percent of enrollees in 10 national and international drug trials for non-small cell lung cancer between 2000 and 2010 were women.

Moreover, although 73 percent of lung cancer patients in the United States are older than 65, only 36 percent of the drug trial population was in that age group.

Blacks also develop lung cancer at higher rates than whites, but they only comprised 2 percent of trial participants in the 10-year period, the study found. Meanwhile, researchers noted that whites made up 78 percent of enrollees, Asians comprised 15 percent, Hispanics 2 percent and "other" accounted for 2 percent.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute provides more information on lung cancer treatment.

-- Mary Elizabeth Dallas

SOURCE: International Association for the Study of Lung Cancer, news release, July 6, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Elderly Dutch lung patients survival improved by new treatment options between 2003-2009
2. Patients at small, isolated, rural hospitals in US more likely to receive lower quality of care
3. ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
4. Worse outcomes for older breast cancer patients with other health problems
5. Heart transplant patients at risk for serious skin cancers
6. Delaying Intravenous Feeding of ICU Patients May Aid Recovery
7. Research Sheds Light on Cause of Brain Deficits in HIV Patients
8. Patients treated with sunitinib and sorafenib respond to flu vaccine
9. Innovative UBC-BC Cancer Agency system reduces waitlisting for chemotherapy patients
10. Team approach reduces urinary tract infections in rehab patients
11. Intensive, hands-on effort reduces bloodstream infections in critically ill patients
Post Your Comments:
Related Image:
Patient Disparities Seen in Lung Cancer Drug Trials
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... medical opinion process, participated in the 61st annual Employee Benefits Conference. The Employee ... took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology: